21st November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Provention Bio receives long-awaited US FDA approval for Diabetes drug

With Sanofi as its marketing partner, after 36 years long wait Provention Bio’s drug Tzield has been approved by the US regulatory body as the first drug to slow the progression of juvenile diabetes in patients aged 8 years and older.

GSK Pharma's consumer trade channel closes impacting 200 employees

In a major restructuring move, GSK decided to put a halt to its consumer trade channel affecting almost 200 mid-level employees who were spread out at various places across cities and involved in trade channels.

Aurobindo Pharma's Sangareddy unit receives 10 USFDA observations

Aurobindo Pharma announced that the Company’s Unit – IX, an intermediate facility situated at Gundlamachnoor Village, Sangareddy District, Telangana has received 10 observations after an inspection conducted (from 10 – 18 November) by the US health authority.

Dr. Reddy's secures second position in list of biggest drugmakers as old order changes

Dr. Reddy’s Laboratories Ltd. and Cipla Ltd. came to the second and third position in the list of biggest drugmakers by sales in the three months to 30 September after competing with Aurobindo pharma.

Sun Pharma gets USFDA approval for drug to treat Neonatal Seizures

On Friday, Sun Pharmaceuticals Ltd. announced that they have received the approval from the US regulatory body for ‘SEZABY’ which is the first and only drug in the US specifically indicated for the treatment of neonatal seizures in term and pre-term neonates.

LIC cuts stake in large-cap pharma stock despite 20% YTD return

Life Insurance Corporation of India (LIC) reduced its stake in the large-cap pharma stock in the second quarter of the current financial year (Q2 FY23) from 5.495 to 4.38 per cent. Whereas, mutual funds increased their stake in Sun Pharma for Q2FY23.

Regeneron Pharma, CytomX Therapeutics join hands to produce bispecific Cancer Therapies

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. have declared a collaboration and agreement to develop conditionally-activated investigational bispecific cancer therapies using CytomX’s therapeutic platform and Regeneron’s VelociBi bispecific antibody development platform.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?